<p>根据 Delta Asset Management LLC TN 最近向证券交易委员会（SEC）提交的文件，该公司在 2023 年第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 15.8%。在此期间，该公司购买了 13,361 股后，持有辉瑞公司 97,994 股股票。根据其最近的 SEC 文件，Delta Asset Management LLC TN 在辉瑞的持股价值为 2,600,000 美元。</p>
<ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p>其他一些对冲基金也对该股票的持仓进行了调整。PSI Advisors LLC 在第四季度将其在辉瑞的持仓提高了 1.4%。PSI Advisors LLC 目前持有 27,823 股辉瑞公司的股票，价值 738,000 美元，此前在上个季度又购买了 385 股。Patriot Financial Group Insurance Agency LLC 在第四季度将其在辉瑞的股份增加了 1.0%。Patriot Financial Group Insurance Agency LLC 目前持有 38,706 股辉瑞公司的股票，价值 1,027,000 美元，此前在上个季度又收购了 391 股。D Orazio &amp; Associates Inc.在第四季度将其在辉瑞的持股提高了 5.5%。D Orazio &amp; Associates Inc.目前持有 7,549 股辉瑞公司的股票，价值 200,000 美元，此前在上个季度又收购了 391 股。Lipe &amp; Dalton 在第四季度将其在辉瑞的持仓提高了 17.7%。Lipe &amp; Dalton 目前持有 2,659 股辉瑞公司的股票，价值 71,000 美元，此前在上个季度又购买了 400 股。最后，Oliver Luxxe Assets LLC 在第四季度将其在辉瑞的股份增加了 2.2%。Oliver Luxxe Assets LLC 目前持有 18,811 股辉瑞公司的股票，价值 499,000 美元，此前在上个季度又购买了 401 股。68.36% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>几位股票研究分析师最近对 PFE 股票发布了报告。Guggenheim 在 3 月 18 日的报告中重申了对辉瑞股票的 “买入” 评级。花旗集团在 1 月 28 日的研究报告中将辉瑞的目标价格从 30.00 美元下调至 29.00 美元，并对该公司设定了 “中性” 评级。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价格从 36.00 美元下调至 32.00 美元，并对该股票设定了 “买入” 评级。美国银行在 12 月 10 日的研究报告中重申了 “中性” 评级，并对辉瑞股票设定了 29.00 美元的目标价格。最后，瑞银集团在 1 月 8 日的报告中将辉瑞的目标价格从 31.00 美元下调至 29.00 美元，并对该股票设定了 “中性” 评级。一位投资分析师对该股票给予了卖出评级，七位分析师给予了持有评级，六位分析师给予了买入评级，三位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 31.92 美元。</p>
<ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
<p><strong>查看我们最新的 PFE 研究报告</strong></p>
<h2>辉瑞内部活动</h2>
<p>在辉瑞的其他新闻中，董事 Ronald E. Blaylock 在 2 月 13 日的交易中购买了 19,457 股该股票。这些股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。收购后，该董事目前直接持有 27,707 股公司的股票，价值 710,684.55 美元。这代表了其持仓的 235.84% 的增长。该交易已在 SEC 的文件中披露，您可以通过此链接访问。当前 0.06% 的股票由公司内部人士持有。</p>
<h2>辉瑞股价下跌 1.4%</h2>
<ul>
<li>在重置年之后，Moderna 股票是否准备好反弹？</li>
</ul>
<p>辉瑞股票在周四开盘价为 25.19 美元。该公司的市值为 1428.8 亿美元，市盈率为 17.87，PEG 比率为 0.64，贝塔值为 0.61。辉瑞公司的 1 年最低价为 24.48 美元，1 年最高价为 31.54 美元。该公司的 50 日简单移动平均线为 26.12 美元，200 日简单移动平均线为 26.98 美元。该公司的流动比率为 1.00，速动比率为 0.73，债务与股本比率为 0.63。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）在 2 月 4 日最后发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.63 美元，超出市场共识预期的 0.48 美元，超出 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司本季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司每股收益为 0.10 美元。该公司的季度收入较去年同期增长了 24.7%。作为一个整体，卖方分析师预计辉瑞公司今年将发布 2.95 的每股收益。</p>
<h2>关于辉瑞</h2>
<p>（免费报告）</p>
<p>辉瑞公司在美国、欧洲及国际上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来可能的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过辉瑞</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>能源转移：通过股息和多元化推动数据</li>
<li>期权交易 - 理解行使价格</li>
<li>高通股票正在蓄势待发</li>
<li>三只值得购买和持有的医疗保健股息股票</li>
<li>在最近的调整后，字母表是否太便宜而无法忽视？</li>
</ul>
<p><strong>想看看其他对辉瑞持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

<p>Delta Asset Management LLC TN 在第四季度增加了对辉瑞（NYSE:PFE）的持股，增幅为 15.8%，目前持有 97,994 股，价值 260 万美元。其他对冲基金也调整了他们的持仓。分析师对辉瑞的评级包括买入和持有的混合评级，普遍评级为 “适度买入”，平均目标价为 31.92 美元。内部人士 Ronald E. Blaylock 购买了 19,457 股，显著增加了他的持股。辉瑞的股票开盘价为 25.19 美元，市值为 1428.8 亿美元，市盈率为 17.87</p>

<p>Delta Asset Management LLC TN grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,994 shares of the biopharmaceutical company's stock after purchasing an additional 13,361 shares during the period. Delta Asset Management LLC TN's holdings in Pfizer were worth $2,600,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Delta Asset Management LLC TN 最近向证券交易委员会（SEC）提交的文件，该公司在 2023 年第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 15.8%。在此期间，该公司购买了 13,361 股后，持有辉瑞公司 97,994 股股票。根据其最近的 SEC 文件，Delta Asset Management LLC TN 在辉瑞的持股价值为 2,600,000 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>维京治疗公司：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p>A number of other hedge funds have also made changes to their positions in the stock. PSI Advisors LLC lifted its position in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after acquiring an additional 391 shares during the last quarter. D Orazio &amp; Associates Inc. raised its holdings in shares of Pfizer by 5.5% during the fourth quarter. D Orazio &amp; Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after acquiring an additional 391 shares in the last quarter. Lipe &amp; Dalton boosted its position in Pfizer by 17.7% during the fourth quarter. Lipe &amp; Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in Pfizer by 2.2% in the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也对该股票的持仓进行了调整。PSI Advisors LLC 在第四季度将其在辉瑞的持仓提高了 1.4%。PSI Advisors LLC 目前持有 27,823 股辉瑞公司的股票，价值 738,000 美元，此前在上个季度又购买了 385 股。Patriot Financial Group Insurance Agency LLC 在第四季度将其在辉瑞的股份增加了 1.0%。Patriot Financial Group Insurance Agency LLC 目前持有 38,706 股辉瑞公司的股票，价值 1,027,000 美元，此前在上个季度又收购了 391 股。D Orazio &amp; Associates Inc.在第四季度将其在辉瑞的持股提高了 5.5%。D Orazio &amp; Associates Inc.目前持有 7,549 股辉瑞公司的股票，价值 200,000 美元，此前在上个季度又收购了 391 股。Lipe &amp; Dalton 在第四季度将其在辉瑞的持仓提高了 17.7%。Lipe &amp; Dalton 目前持有 2,659 股辉瑞公司的股票，价值 71,000 美元，此前在上个季度又购买了 400 股。最后，Oliver Luxxe Assets LLC 在第四季度将其在辉瑞的股份增加了 2.2%。Oliver Luxxe Assets LLC 目前持有 18,811 股辉瑞公司的股票，价值 499,000 美元，此前在上个季度又购买了 401 股。68.36% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities research analysts have recently issued reports on PFE shares. Guggenheim reiterated a &#34;buy&#34; rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, January 28th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, December 18th. Bank of America reaffirmed a &#34;neutral&#34; rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a &#34;neutral&#34; rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $31.92.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 PFE 股票发布了报告。Guggenheim 在 3 月 18 日的报告中重申了对辉瑞股票的 “买入” 评级。花旗集团在 1 月 28 日的研究报告中将辉瑞的目标价格从 30.00 美元下调至 29.00 美元，并对该公司设定了 “中性” 评级。Truist Financial 在 12 月 18 日的研究报告中将辉瑞的目标价格从 36.00 美元下调至 32.00 美元，并对该股票设定了 “买入” 评级。美国银行在 12 月 10 日的研究报告中重申了 “中性” 评级，并对辉瑞股票设定了 29.00 美元的目标价格。最后，瑞银集团在 1 月 8 日的报告中将辉瑞的目标价格从 31.00 美元下调至 29.00 美元，并对该股票设定了 “中性” 评级。一位投资分析师对该股票给予了卖出评级，七位分析师给予了持有评级，六位分析师给予了买入评级，三位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 31.92 美元。</p>
</div><ul>
<li>These Stocks Missed on Earnings, But Will Rebound Next Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>这些股票的收益未达预期，但下季度将反弹</li>
</ul>
</div><p><strong>View Our Latest Research Report on PFE</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 PFE 研究报告</strong></p>
</div><h2>Insider Activity at Pfizer</h2>
<div class="lb-trans"><h2>辉瑞内部活动</h2>
</div><p>In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在辉瑞的其他新闻中，董事 Ronald E. Blaylock 在 2 月 13 日的交易中购买了 19,457 股该股票。这些股票的平均购买价格为每股 25.65 美元，总价值为 499,072.05 美元。收购后，该董事目前直接持有 27,707 股公司的股票，价值 710,684.55 美元。这代表了其持仓的 235.84% 的增长。该交易已在 SEC 的文件中披露，您可以通过此链接访问。当前 0.06% 的股票由公司内部人士持有。</p>
</div><h2>Pfizer Trading Down 1.4 %</h2>
<div class="lb-trans"><h2>辉瑞股价下跌 1.4%</h2>
</div><ul>
<li>After a Reset Year, Is Moderna Stock Poised for a Comeback?</li>
</ul>
<div class="lb-trans"><ul>
<li>在重置年之后，Moderna 股票是否准备好反弹？</li>
</ul>
</div><p>Shares of Pfizer stock opened at $25.19 on Thursday. The company has a market cap of $142.88 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company's fifty day simple moving average is $26.12 and its 200-day simple moving average is $26.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.</p>
<div class="lb-trans"><p>辉瑞股票在周四开盘价为 25.19 美元。该公司的市值为 1428.8 亿美元，市盈率为 17.87，PEG 比率为 0.64，贝塔值为 0.61。辉瑞公司的 1 年最低价为 24.48 美元，1 年最高价为 31.54 美元。该公司的 50 日简单移动平均线为 26.12 美元，200 日简单移动平均线为 26.98 美元。该公司的流动比率为 1.00，速动比率为 0.73，债务与股本比率为 0.63。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the previous year, the company posted $0.10 earnings per share. The company's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）在 2 月 4 日最后发布了季度财报。这家生物制药公司报告本季度每股收益（EPS）为 0.63 美元，超出市场共识预期的 0.48 美元，超出 0.15 美元。辉瑞的股本回报率为 19.47%，净利润率为 12.62%。该公司本季度的收入为 177.6 亿美元，而分析师预期为 172.6 亿美元。在去年同期，该公司每股收益为 0.10 美元。该公司的季度收入较去年同期增长了 24.7%。作为一个整体，卖方分析师预计辉瑞公司今年将发布 2.95 的每股收益。</p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>关于辉瑞</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p>
<div class="lb-trans"><p>辉瑞公司在美国、欧洲及国际上发现、开发、生产、营销、分销和销售生物制药产品。该公司在多个治疗领域提供药物和疫苗，包括心血管代谢、偏头痛和女性健康，旗下品牌包括 Eliquis、Nurtec ODT/Vydura、Zavzpret 和 Premarin 系列；在满足医疗需求的传染病领域，旗下品牌包括 Prevnar 系列、Abrysvo、Nimenrix、FSME/IMMUN-TicoVac 和 Trumenba；以及 COVID-19 的预防和治疗，以及未来可能的 mRNA 和抗病毒产品，旗下品牌包括 Comirnaty 和 Paxlovid。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Energy Transfer: Powering Data With Dividends and Diversification</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Qualcomm Stock Is Coiling for a Breakout</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Is Alphabet Too Cheap to Ignore After Its Recent Correction?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过辉瑞</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>能源转移：通过股息和多元化推动数据</li>
<li>期权交易 - 理解行使价格</li>
<li>高通股票正在蓄势待发</li>
<li>三只值得购买和持有的医疗保健股息股票</li>
<li>在最近的调整后，字母表是否太便宜而无法忽视？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对辉瑞持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer Inc. (NYSE:PFE) Stake Raised by Delta Asset Management LLC TN

- Delta Asset Management 增持 Pfizer 15.8%，持股达 97,994 股，市值 260 万美元。  
- 多家对冲基金调整持仓，PSI Advisors 增持 1.4%，Patriot Financial 增持 1.0%。  
- Pfizer 第四季度营收 177.6 亿美元，超出预期，EPS 为 0.63 美元。  

Delta Asset Management LLC TN 增持辉瑞公司（纽约证券交易所代码：PFE）的股份